Brainwide silencing of prion protein by AAV-mediated delivery of an engineered compact epigenetic editor

Edwin N. Neumann(Whitehead Institute for Biomedical Research), Tessa M. Bertozzi(Howard Hughes Medical Institute), Elaine Wu(Whitehead Institute for Biomedical Research), Fiona E. Serack(Broad Institute), John W. Harvey(Broad Institute), Pamela P. Brauer(Broad Institute), Catherine P. Pirtle(Broad Institute), Alissa A Coffey(Broad Institute), Michael W. Howard(Broad Institute), Nikita Kamath(Broad Institute), Kenney Lenz(Broad Institute), Kenia Guzman(Broad Institute), Michael H. Raymond(Boston University), Ahmad S. Khalil(Boston University), Benjamin E. Deverman(Broad Institute), Eric Vallabh Minikel(Broad Institute), Sonia M. Vallabh(Broad Institute), Jonathan S. Weissman(Howard Hughes Medical Institute)
Science
June 27, 2024
Cited by 98Open Access
Full Text

Abstract

Prion disease is caused by misfolding of the prion protein (PrP) into pathogenic self-propagating conformations, leading to rapid-onset dementia and death. However, elimination of endogenous PrP halts prion disease progression. In this study, we describe Coupled Histone tail for Autoinhibition Release of Methyltransferase (CHARM), a compact, enzyme-free epigenetic editor capable of silencing transcription through programmable DNA methylation. Using a histone H3 tail-Dnmt3l fusion, CHARM recruits and activates endogenous DNA methyltransferases, thereby reducing transgene size and cytotoxicity. When delivered to the mouse brain by systemic injection of adeno-associated virus (AAV), Prnp -targeted CHARM ablates PrP expression across the brain. Furthermore, we have temporally limited editor expression by implementing a kinetically tuned self-silencing approach. CHARM potentially represents a broadly applicable strategy to suppress pathogenic proteins, including those implicated in other neurodegenerative diseases.


Related Papers